A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
Status:
Terminated
Trial end date:
2011-12-22
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, and the maximum tolerated dose (MTD) of
MK-2206 in combination with both trastuzumab and trastuzumab/lapatinib in participants with
human epidermal growth factor receptor 2 positive (HER2+) breast cancer and other solid
tumors. The primary hypothesis of this study is that the combination of oral MK-2206 with
trastuzumab or with trastuzumab/lapatinib will be well tolerated in participants with
advanced HER2+ solid tumors.